Loading...
•
Jun 30, 2021
Edgewise Therapeutics Q2 2021 Earnings Report
Financial results reported for the second quarter of 2021 and recent business highlights announced.
Key Takeaways
Edgewise Therapeutics reported cash, cash equivalents and marketable securities of $299 million as of June 30, 2021. Net loss for the second quarter of 2021 was $10.4 million, or $0.21 per share.
Advanced Phase 1 MAD study of EDG-5506 for Duchenne and Becker muscular dystrophy (DMD and BMD).
Cash and marketable securities totaled $299 million as of June 30, 2021.
Presented research at the New Directions in Biology and Disease of Skeletal Muscle Conference.
Advanced preclinical research programs, including EDG-002 targeting inherited hypertrophic cardiomyopathy (HCM).
Edgewise Therapeutics
Edgewise Therapeutics
Forward Guidance
The company expects to have topline MAD data from the Phase 1a MAD and Phase 1b Becker cohorts towards the end of 2021.